Amsterdam Pharmaceuticals Discloses Equity Incentive Awards Under Nasdaq Listing Standards

New Amsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)

NEW YORK, April 4, 2025 /GLOBE NEWSWIRE/ -- New Amsterdam Pharma, Inc. (Nasdaq: NAP) today announced that it has granted inducement stock options to certain new employees of the company, as permitted by Nasdaq Listing Rule 5635(c).

The options were granted on April 1, 2025, and are subject to the terms and conditions of the company's 2025 Equity Incentive Plan. The options have an exercise price of $20.00 per share, which is the closing price of the company's common stock on the grant date, and will vest in four equal installments over a period of four years, with the first installment vesting on the one-year anniversary of the grant date.

The options were granted to the following new employees:

• [Name], [Title], effective April 1, 2025
• [Name], [Title], effective April 1, 2025

The aggregate number of options granted was 100,000, and the total value of the options, based on the grant date closing price of the company's common stock, was approximately $2,000,000.

New Amsterdam Pharma is a biopharmaceutical company focused on the development and commercialization of innovative treatments for patients with significant unmet medical needs. The company's lead product candidate is [Product Name], a novel treatment for [Disease/Condition].

For more information, please visit our website at [Company Website].